EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Application of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial

Faith Anne N Heeren iD, Kathleen R Ruddiman iD, Courtney Simmons iD, Brian N White, Byron C Jaeger, Nicholas M Pajewski, Stephanie A Hooker iD, Deborah B Horn, Katy Martin-Fernandez, Kimberly A Gudzune iD, Caroline Blackwell Young, Jamy Ard und 1 weitere

Obesity · 2026-01 · 34 (1) · 58-64

DOI: 10.1002/oby.70070 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Obesity, online erschienen am 27.10.2025. Verfasst von Faith Anne N Heeren und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. Hauptthemen laut MEDLINE: Obesity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NHLBI NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to apply The Lancet Diabetes & Endocrinology criteria for diagnosing obesity among clinical trial participants and understand participants' characteristics by obesity status.

Methods

The criteria were operationalized and applied to baseline data from the Long‐term Effectiveness of the Anti‐obesity medication Phentermine (LEAP) trial (NCT05176626). Excess adiposity, organ and tissue dysfunction, and limitations to daily activities were assessed. We examined differences between participants with “no obesity,” “pre‐clinical obesity,” and “clinical obesity.” Results Among the 860 participants, 0.8% had no obesity (mean BMI 29.0 kg/m 2 [SD 0.6]), 18.7% had pre‐clinical obesity (mean BMI 35.2 kg/m 2 [SD 3.5]), and 80.5% had clinical obesity (mean BMI 35.9 kg/m 2 [SD 4.3]). Participants with no/pre‐clinical obesity had lower mean SF‐12 mental component scores and greater baseline engagement with weight control strategies compared to those with clinical obesity. Participants with clinical obesity were older and, by definition, had a greater burden of cardiometabolic risk factors.

Conclusions

Among clinical trial participants eligible for obesity pharmacotherapy, 19.5% were classified as having no/pre‐clinical obesity using the Lancet criteria. Applying the criteria was complicated in a well‐resourced trial setting, which suggests potential challenges in implementing these guidelines in real‐world practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityAdultAgedFemaleHumansMaleMiddle AgedAdiposityAnti-Obesity AgentsBody Mass IndexPhentermine

Stichwörter der Autor:innen

clinical carediagnosisobesity medicationobesity treatmentpharmacotherapy

Substanzen

Anti-Obesity AgentsPhentermine

Autor:innen und Institutionen

  • Department of Implementation Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Internal Medicine, Endocrinology Section, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • HealthPartners Institute, Minneapolis, Minnesota, USA.
  • Department of Family Medicine and Community Health, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Surgery, University of Texas McGovern Medical School, Houston, Texas, USA.

ORCID-Profile: Faith Anne N Heeren, Kathleen R Ruddiman, Courtney Simmons, Stephanie A Hooker, Kimberly A Gudzune, Kristina Henderson Lewis

Förderung

  • NCATS NIH HHS
  • NHLBI NIH HHS
  • NCI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Heeren, F. A. N., Ruddiman, K. R., Simmons, C., White, B. N., Jaeger, B. C., Pajewski, N. M., Hooker, S. A., Horn, D. B., Martin-Fernandez, K., Gudzune, K. A., Young, C. B., Ard, J., & Lewis, K. H. (2026). Application of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial. Obesity, 34(1), 58-64. https://doi.org/10.1002/oby.70070

Vancouver

Heeren FAN, Ruddiman KR, Simmons C, White BN, Jaeger BC, Pajewski NM, et al. Application of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial. Obesity. 2026;34(1):58-64. doi:10.1002/oby.70070

BibTeX
@article{Heeren2026,
  author = {Heeren, Faith Anne N and Ruddiman, Kathleen R and Simmons, Courtney and White, Brian N and Jaeger, Byron C and Pajewski, Nicholas M and Hooker, Stephanie A and Horn, Deborah B and Martin-Fernandez, Katy and Gudzune, Kimberly A and Young, Caroline Blackwell and Ard, Jamy and Lewis, Kristina Henderson},
  title = {Application of the Lancet Commission Criteria for the Diagnosis of Obesity to a Clinical Trials Population: The LEAP Trial},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {1},
  pages = {58--64},
  doi = {10.1002/oby.70070}
}
Kostenlos starten →